-
公开(公告)号：EP0663912A4
公开(公告)日：1995-02-17
申请号：EP93923826
申请日：1993-10-08
Applicant: ABBOTT LAB
Inventor： ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , ELLIOTT RICHARD L , GARVEY DAVID S , LEBOLD SUZANNE A , WASICAK JAMES T
IPC: A61K31/427 , A61K31/439 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P25/00 , A61P25/28 , C07D401/12 , C07D403/12 , C07D411/12 , C07D417/12 , C07D471/08 , C07D487/04 , A61K31/425 , A61K31/445 , A61K31/495 , A61K31/50 , A61K31/505 , C07D453/02
CPC classification number: C07D401/12 , C07D403/12 , C07D417/12
-
公开(公告)号：AT262519T
公开(公告)日：2004-04-15
申请号：AT98964167
申请日：1998-12-18
Applicant: ABBOTT LAB
Inventor： HOLLADAY MARK W , ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , GARVEY DAVID S , RYTHER KEITH , LEBOLD SUZANNE A , ELLIOTT RICHARD L , HE YUN , WASIAK JAMES T , BAI HAO , DART MICHAEL J , EHRLICH PAUL P , LI YIHONG , KINCAID JOHN F , SCHKERYANTZ JEFFREY M , LYNCH JOHN K
IPC: A61K31/427 , A61K31/4427 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61P25/00 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D401/12 , C07D403/12 , C07D417/12 , C07D455/02 , C07D487/04 , A61K31/40 , A61K31/425 , A61K31/44
-
公开(公告)号：ES2221234T3
公开(公告)日：2004-12-16
申请号：ES98964167
申请日：1998-12-18
Applicant: ABBOTT LAB
Inventor： HOLLADAY MARK W , ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , GARVEY DAVID S , RYTHER KEITH
IPC: A61K31/427 , A61K31/4427 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61P25/00 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D401/12 , C07D403/12 , C07D417/12 , C07D455/02 , C07D487/04 , A61K31/40 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/50 , A61K31/505
Abstract: Compuesto teniendo la fórmula (I): **(Fórmula)** o una sal o profármaco del mismo farmacéuticamente admisible, en donde B es **(Fórmula)** en donde R3 es H o alquilo C1-C6; X se selecciona del grupo que se compone de oxígeno y azufre; y E es **(Fórmula)** en donde y es un número entero seleccionado de entre 2 y 3, con los requisitos de que (a) cuando y = 2, R4 se selecciona del grupo que tiene sustituyentes en las posiciones 2, 4-, 2, 5-, 2, 6-, 4, 5-, 4, 6- y 5, 6-del anillo piridina, en donde un sustituyente en la posición 2 es seleccionado del grupo que se compone de (i) -Br, (ii) -Cl, (iii) -F, (iv) -OH, (v) -NH2, (vi) -alquilo C1-C4, y (vii) -alcoxi C1-C3.
-
公开(公告)号：CA2136075C
公开(公告)日：2004-12-14
申请号：CA2136075
申请日：1993-10-08
Applicant: ABBOTT LAB
Inventor： ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , ELLIOTT RICHARD L , GARVEY DAVID S , LEBOLD SUZANNE A , WASICAK JAMES T
IPC: A61K31/427 , A61K31/439 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P25/00 , A61P25/28 , C07D401/12 , C07D403/12 , C07D411/12 , C07D417/12 , C07D471/08 , C07D487/04 , C07D453/02 , A61K31/425 , A61K31/435 , A61K31/495
Abstract: Novel heterocyclic ether compounds of formula (I), wherein A, B and R2 are specifically defined, or pharmaceutically- acceptable salts or prodrugs thereof, which are selective and potent ligands at cholinergic channel receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.
-
公开(公告)号：DK1047690T3
公开(公告)日：2004-07-05
申请号：DK98964167
申请日：1998-12-18
Applicant: ABBOTT LAB
Inventor： HOLLADAY MARK W , ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , GARVEY DAVID S , RYTHER KEITH , LEBOLD SUZANNE A , ELLIOTT RICHARD L , HE YUN , WASIAK JAMES T , BAI HAO , DART MICHAEL J , EHRLICH PAUL P , LI YIHONG , KINCAID JOHN F , SCHKERYANTZ JEFFREY M , LYNCH JOHN K
IPC: A61K31/427 , A61K31/4427 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61P25/00 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D401/12 , C07D403/12 , C07D417/12 , C07D455/02 , C07D487/04 , A61K31/40 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/50 , A61K31/505
-
Patent Agency Ranking
公开(公告)号：AU5355794A
公开(公告)日：1994-05-09
申请号：AU5355794
申请日：1993-10-08
Applicant: ABBOTT LAB
Inventor： ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , ELLIOTT RICHARD L , GARVEY DAVID S , LEBOLD SUZANNE A , WASICAK JAMES T
IPC: A61K31/427 , A61K31/439 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P25/00 , A61P25/28 , C07D401/12 , C07D403/12 , C07D411/12 , C07D417/12 , C07D471/08 , C07D487/04 , A61K31/425 , A61K31/445 , A61K31/495 , A61K31/50 , A61K31/505
Abstract: Novel heterocyclic ether compounds of formula (I), wherein A, B and R are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are selective and potent ligands at cholinergic channel receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.
-
公开(公告)号：MX9306274A
公开(公告)日：1994-04-29
申请号：MX9306274
申请日：1993-10-08
Applicant: ABBOTT LAB
Inventor： ELLIOTT RICHARD L , LEBOLD SUZANNE A , WASICAK JAMES T , GARVEY DAVID S , ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG
IPC: C07D403/12
-
公开(公告)号：PT1047690E
公开(公告)日：2004-07-30
申请号：PT98964167
申请日：1998-12-18
Applicant: ABBOTT LAB
Inventor： ABREO MELWYN A , DART MICHAEL J , LIN NAN-HORNG , LYNCH JOHN K , LEBOLD SUZANNE A , GUNN DAVID E , GARVEY DAVID S , ELLIOTT RICHARD L , HOLLADAY MARK W , RYTHER KEITH , HE YUN , WASIAK JAMES T , BAI HAO , EHRLICH PAUL P , LI YIHONG , KINCAID JOHN F , SCHKERYANTZ JEFFREY M
IPC: A61K31/427 , A61K31/4427 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61P25/00 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D401/12 , C07D403/12 , C07D417/12 , C07D455/02 , C07D487/04 , A61K31/40 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/50 , A61K31/505
-
公开(公告)号：DE69331329T2
公开(公告)日：2002-08-08
申请号：DE69331329
申请日：1993-10-08
Applicant: ABBOTT LAB
Inventor： ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , ELLIOTT RICHARD L , GARVEY DAVID S , LEBOLD SUZANNE A , WASICAK JAMES T
IPC: A61K31/427 , A61K31/439 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P25/00 , A61P25/28 , C07D401/12 , C07D403/12 , C07D411/12 , C07D417/12 , C07D471/08 , C07D487/04 , A61K31/425 , A61K31/445 , A61K31/495 , A61K31/50 , A61K31/505
Abstract: Novel heterocyclic ether compounds of formula (I), wherein A, B and R are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are selective and potent ligands at cholinergic channel receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.
-
公开(公告)号：DK0663912T3
公开(公告)日：2002-04-15
申请号：DK93923826
申请日：1993-10-08
Applicant: ABBOTT LAB
Inventor： ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , ELLIOTT RICHARD L , GARVEY DAVID S , LEBOLD SUZANNE A , WASICAK JAMES T
IPC: A61K31/427 , A61K31/439 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P25/00 , A61P25/28 , C07D401/12 , C07D403/12 , C07D411/12 , C07D417/12 , C07D471/08 , C07D487/04 , A61K31/425 , A61K31/445 , A61K31/495 , A61K31/50 , A61K31/505 , C07D453/02
Abstract: Novel heterocyclic ether compounds of formula (I), wherein A, B and R are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are selective and potent ligands at cholinergic channel receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.019 seconds)
